Trial of a Falciparum Malaria Protein (FMP012), E. Coli-expressed PfCelTOS, in Healthy Malaria-Naive Adults

* Healthy adults (male or non-pregnant, non-lactating female) 18 to 50 years of age at the time of screening * If the subject is female, * Non-childbearing potential , abstinent or using adequate contraceptive precautions during this study and must agree to continue such precautions until three months after challenge * A negative pregnancy test at the time of enrollment * Free of significant health problems as established by medical history, laboratory, and clinical examination before entering the study * Low cardiac risk factors * Available to participate and reachable by phone for duration of study (approximately 8 months) * No plans to travel to outside the Washington DC area between the day of challenge and either completion of treatment course (post-challenge) or, if subject remains uninfected, 28 days post-challenge * No plans to travel to a malaria endemic area during the course of the study * Written informed consent must be obtained from the subject before screening procedures * Subjects must score at least 80% correct on a multiple-choice quiz that assesses their understanding of this study * Active duty military must obtain approval from his or her supervisor Exclusion Criteria: * History of malaria infection * History of travel to P. falciparum endemic areas in the 3 months prior to day of first vaccination or day of challenge * History of receiving a malaria vaccine * Receipt of any licensed vaccine within 7 days prior to first vaccination * History of receipt of malaria prophylaxis during the 2 months prior to day of first vaccination or day of challenge * History of use of any drugs with significant antimalarial activity during the course of the study period * Prior receipt of any vaccine containing either QS-21, MPL or GLA-SE in the previous 5 years (including Cervarix®, GSK) * Use of any investigational or non-registered drug or vaccine within 30 days preceding the first dose of study vaccine or planned use during the study period. * Any history of allergic reaction or anaphylaxis to previous vaccination * Allergy to kanamycin, nickel, or imidazole Pregnant or lactating female at screening or plans to become pregnant or breastfeed from the time of enrollment until three months after challenge * Allergy to antimalarial drugs or use of medications known to interact with both CQ and artemether/lumefantrine * Significant (eg, systemic) hypersensitivity reactions to mosquito bites * History of sickle cell disease * History of psoriasis or porphyria * History of splenectomy * Any confirmed or suspected immunodeficiency, including HIV infection * Administration of chronic (defined as more than 14 days) immunosuppressive drugs or other immune-modifying drugs within six months of vaccination * Inhaled and topical steroids are allowed * A family history of congenital or hereditary immunodeficiency * Acute or chronic, clinically significant, pulmonary, cardiovascular, hepatic, or renal functional abnormality, as determined by history, physical examination, or laboratory evaluation * Chronic or active neurologic disease including seizure disorder and chronic migraine headaches * Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or any planned administration during the study period * Any abnormal baseline laboratory screening tests listed below (normal values are defined in the adverse event section of this protocol): * Seropositive for HIV or Hepatitis C virus or HBsAg positive * Hepatomegaly, right upper quadrant abdominal pain or tenderness * An abnormal baseline screening EKG. * Suspected or known current alcohol or drug abuse as determined from the medical history or by physical examination * Any other significant finding that in the opinion of the PI would increase the risk of having an adverse outcome from participating in this study